List of Excipients in Branded Drug ARIXTRA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	ARIXTRA	fondaparinux sodium	54868-5652	SODIUM CHLORIDE
Physicians Total Care Inc	ARIXTRA	fondaparinux sodium	54868-5652	WATER
Mylan Institutional LLC	ARIXTRA	fondaparinux sodium	67457-592	SODIUM CHLORIDE
Mylan Institutional LLC	ARIXTRA	fondaparinux sodium	67457-592	WATER

Arixtra Excipient Strategy and Commercial Opportunities for Fondaparinux Sodium

Last updated: September 5, 2026

Arixtra is a sterile, preservative-free aqueous injection containing the synthetic pentasaccharide anticoagulant fondaparinux sodium. Its excipient profile is deliberately narrow: sodium chloride, water for injection, and pH-adjusting agents. Commercial opportunities are concentrated in generic fondaparinux, prefilled-syringe platforms, stability improvements, hospital supply contracts, and differentiated injectable presentations rather than in complex reformulation.

What excipients does Arixtra contain?

Arixtra uses a minimal parenteral formulation designed for subcutaneous administration in single-use prefilled syringes.

Component	Function	Commercial implication
Fondaparinux sodium	Active anticoagulant	Synthetic, highly sulfated pentasaccharide
Sodium chloride	Isotonicity adjustment	Low-cost, familiar injectable excipient
Water for injection	Vehicle	Standard sterile aqueous medium
Hydrochloric acid or sodium hydroxide	pH adjustment	Supports product stability and injectability
Preservatives	None listed	Enables single-dose, preservative-free positioning

The US prescribing information identifies sodium chloride and water for injection as inactive ingredients and states that pH may be adjusted with hydrochloric acid or sodium hydroxide. Arixtra is supplied as a clear, colorless sterile solution in single-dose syringes (U.S. Food and Drug Administration [FDA], 2023).

The formulation has several commercial advantages:

• No benzyl alcohol or other antimicrobial preservative.
• No surfactant-heavy system.
• No lyophilization cycle.
• No reconstitution step.
• No animal-derived excipient.
• No need for a complex depot or sustained-release matrix.

The product is supplied in 2.5 mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL, and 10 mg/0.8 mL strengths. The different concentrations support prophylaxis and treatment dosing while maintaining a ready-to-use subcutaneous presentation.

How does the Arixtra formulation affect generic development?

Generic development is technically simpler than development of a biologic, liposomal injection, or long-acting depot. The principal challenge is not excipient novelty. It is demonstrating pharmaceutical equivalence, chemical purity, sterility, particulate control, container-closure integrity, and comparable device performance.

Fondaparinux is a highly sulfated synthetic oligosaccharide. Its quality profile is more demanding than that of a conventional small-molecule anticoagulant because the product requires control of:

• Sulfation pattern.
• Chain identity and structural integrity.
• Degree of substitution.
• Residual solvents and reagents.
• Counterion content.
• Related oligosaccharides.
• Endotoxin and bioburden.
• Subvisible particles.
• pH and osmolality.
• Container interaction.

The formulation itself creates a relatively low barrier to entry. Sodium chloride and water for injection are widely available, and pH adjustment is routine. The higher barrier lies in active-ingredient synthesis, impurity characterization, validated assays, sterile filling, and supply reliability.

Under FDA abbreviated new drug application practice, a generic applicant generally seeks the same dosage form, strength, route of administration, and active ingredient. A materially different excipient system could increase regulatory risk if it changes injection-site tolerability, stability, osmolality, or immunogenicity-related concerns.

What formulation patents protect Arixtra?

The original patent estate for fondaparinux covered the synthetic pentasaccharide, its preparation, and anticoagulant use. The foundational composition and process patents were filed in the 1990s and have generally reached expiration in major markets.

The commercial protection profile is now primarily shaped by:

1. Expired foundational patents.
2. Regulatory approval history.
3. Manufacturing know-how.
4. Supplier qualification.
5. Sterile injectable capacity.
6. Hospital contracting and distribution.

The FDA Orange Book is the principal source for US patents listed against approved products. It should be distinguished from patent databases and court records: an Orange Book listing does not capture every potentially relevant process, manufacturing, trade-secret, or foreign patent right (FDA, 2024).

Patent and exclusivity timeline

Event	Approximate timing	Commercial effect
Foundational fondaparinux patent filings	Early to mid-1990s	Established composition and manufacturing protection
FDA approval of Arixtra	December 2001	Created US regulatory exclusivity and branded market access
Original five-year new chemical entity exclusivity	Expired in 2006	Allowed ANDA pathway after statutory exclusivity
Core patent term expiration	Generally late 2000s to early 2010s	Removed the principal composition barrier
Generic approvals	Beginning in the late 2010s	Increased price and contracting pressure
Current market	Generic and branded supply	Competitive focus shifted to cost, quality, and availability

The Hatch-Waxman five-year new chemical entity period for the original US approval expired long before the current commercial period. Patent term adjustment, pediatric exclusivity, and jurisdiction-specific supplementary protection rights can affect individual markets, but they do not recreate broad global exclusivity for the Arixtra formulation.

When did Arixtra lose exclusivity?

Arixtra lost meaningful US regulatory exclusivity after the expiration of its five-year new chemical entity period in 2006. The relevant composition and manufacturing patent barriers also expired over subsequent years. Generic fondaparinux products were later approved in the US, confirming that the product was no longer protected by a complete market-entry block.

The remaining commercial protection is weaker than patent exclusivity. It depends on:

• FDA-approved manufacturing capacity.
• Active pharmaceutical ingredient availability.
• Hospital formulary contracts.
• Product shortages or supply interruptions.
• Device and packaging reliability.
• Brand familiarity in perioperative care.
• Procurement preferences for established suppliers.

What is the Orange Book status of Arixtra?

Arixtra is listed in FDA drug-product records under fondaparinux sodium injection. The Orange Book identifies approved products, reference listed drug status, dosage forms, strengths, and any listed patent or exclusivity information applicable to the relevant product record (FDA, 2024).

The key regulatory conclusion is that fondaparinux is an ANDA-accessible small-molecule injectable product. It does not require a biosimilar application. Applicants pursue an ANDA rather than a 351(k) biologics license application pathway.

Orange Book status does not eliminate other risks. A generic applicant still must address:

• Active-ingredient sameness.
• Injectable product quality.
• Sterility assurance.
• Device equivalence.
• Labeling requirements.
• Manufacturing inspection readiness.
• Patent certifications under Paragraph I, II, III, or IV.

Which companies are challenging Arixtra through generic entry?

Generic fondaparinux has been developed and marketed by multiple pharmaceutical companies, including firms active in sterile injectables and hospital products. FDA product records identify approved generic presentations and their application holders; the competitive field can change as products enter, exit, or become supply constrained.

The commercial challengers are not limited to traditional retail-generic companies. Relevant competitors include:

• Sterile injectable specialists.
• Contract manufacturers with injectable capacity.
• Hospital-focused generic companies.
• International manufacturers seeking US or European approval.
• Suppliers with vertically integrated fondaparinux API production.

A Paragraph IV certification would be relevant only if an applicant challenged an unexpired Orange Book patent. Because the core Arixtra patent estate is mature, later entrants have had greater opportunity to rely on non-infringement, invalidity, or Paragraph III strategies. The most important entry issue is now execution rather than patent clearance.

Is there biosimilar risk for Arixtra?

Arixtra has no conventional biosimilar risk because fondaparinux is a synthetic pentasaccharide drug, not a protein biologic. The competitive threat comes from generic equivalents and therapeutic substitution, not biosimilar interchangeability.

This distinction affects commercial strategy:

Issue	Arixtra position
FDA pathway	ANDA for generic products
Reference product	Arixtra injection
Biosimilar pathway	Not applicable
Interchangeability	Governed by generic substitution and state law, not biologic interchangeability
Main competitive risk	Lower-cost fondaparinux and alternative anticoagulants

Competing anticoagulants include enoxaparin, dalteparin, unfractionated heparin, and direct oral anticoagulants. Fondaparinux retains a differentiated role in selected surgical, thromboembolic, and heparin-related clinical settings, but hospitals often evaluate it against lower-cost alternatives.

What excipient strategies can improve generic fondaparinux?

The best strategy is usually conservative excipient matching rather than aggressive reformulation.

Strategy 1: Match the reference formulation

A generic applicant can use sodium chloride and water for injection with conventional pH adjustment. This minimizes clinical and regulatory differentiation risk.

The benefits are predictable:

• Lower formulation-development cost.
• Familiar toxicology profile.
• Easier comparability assessment.
• Lower risk of injection-site reactions.
• Compatibility with existing sterile-fill equipment.

Strategy 2: Develop a low-volume presentation

A lower-volume syringe could improve injection convenience, reduce packaging material, and increase shipping efficiency. The limitation is that changing concentration may create a new strength or presentation requiring additional regulatory justification.

Strategy 3: Optimize container closure

A prefilled syringe is a major commercial component of Arixtra. Opportunities include:

• Low-silicone syringes.
• Reduced tungsten exposure.
• Low-extractable elastomers.
• Improved needle-shield integrity.
• Automated needle-safety systems.
• Better plunger glide.
• Reduced dead volume.

For a highly charged oligosaccharide, container interaction and adsorption testing are important. Silicone oil, elastomer extractables, and surface interaction can affect particulate levels or assay recovery.

Strategy 4: Improve cold-chain resilience

A ready-to-use aqueous injection benefits from a broad validated storage range. A manufacturer that demonstrates robust stability under temperature excursions can reduce distribution losses and improve hospital inventory management.

Relevant studies include:

• Long-term stability.
• Accelerated stability.
• Photostability.
• Freeze-thaw exposure.
• Shipping vibration.
• Syringe integrity.
• Extractables and leachables.
• In-use handling.

The opportunity is commercial rather than patent-driven. A better stability profile can support tenders and reduce returns without materially changing the excipient system.

Strategy 5: Develop preservative-free multidose alternatives cautiously

A preservative-free multidose format could reduce unit packaging, but it would introduce sterility, microbial-control, and in-use stability issues. It would also depart from the established single-dose risk profile. The development case is weaker than improving the existing prefilled-syringe platform.

What manufacturing and intellectual-property barriers affect fondaparinux?

The main barrier is the active ingredient. Fondaparinux requires controlled multistep synthesis and purification of a structurally defined, highly sulfated pentasaccharide. The manufacturing process must consistently deliver the required stereochemistry, sulfation, counterion composition, and impurity profile.

Manufacturing barriers

• Specialized carbohydrate chemistry.
• High-cost starting materials.
• Multiple protection and deprotection steps.
• Sulfation control.
• Difficult purification.
• Low tolerance for structural impurities.
• Specialized analytical characterization.
• Limited qualified API suppliers.
• Sterile injectable manufacturing capacity.

IP barriers

Expired composition patents do not eliminate process know-how. Manufacturers may still protect:

• Improved synthetic routes.
• Purification processes.
• Crystallization or salt-selection techniques.
• Analytical methods.
• High-yield intermediates.
• Continuous manufacturing processes.
• Device and packaging configurations.

These rights may support licensing or freedom-to-operate negotiations even when the principal Arixtra product patents have expired.

What licensing deals affect Arixtra commercial opportunities?

Arixtra has had different commercial arrangements across regions and over time, involving originator, license, and distribution structures. FDA product records do not function as a complete database of private licensing agreements.

For current business planning, the relevant licensing opportunities are more likely to involve:

• Fondaparinux API supply.
• Regional sterile-fill rights.
• Prefilled-syringe technology.
• Hospital distribution.
• Contract manufacturing.
• Analytical method transfer.
• Regulatory dossiers for emerging markets.

A company with qualified API and sterile-fill capacity can create value without owning a new excipient patent. The strongest deal structure would combine reliable API supply with an approved or approval-ready syringe presentation.

What patent litigation affects Arixtra?

The principal US patent dispute risk is lower than for recently launched branded drugs because the foundational Arixtra exclusivity period has ended and generic products have entered the market. Litigation exposure can still arise from:

• Process patents.
• Manufacturing improvements.
• Device patents.
• Formulation or container patents.
• ANDA Paragraph IV certifications.
• Contract disputes between suppliers and manufacturers.
• Foreign-market patent rights.

A generic company should separate three questions:

1. Is the active ingredient free of blocking composition patents?
2. Does the manufacturing route practice a surviving process claim?
3. Does the proposed syringe or safety device infringe a separate patent?

That analysis is more important than searching for a single “Arixtra patent.”

What generic launch scenarios exist for Arixtra?

Low-cost commodity launch

The applicant matches the reference excipients, uses a standard prefilled syringe, and competes on price. This approach has the lowest development risk but also the weakest differentiation.

Supply-reliability launch

The applicant positions the product around consistent availability, dual API sourcing, and hospital-contract performance. This can support share gains in a shortage-sensitive injectable market.

Device-differentiated launch

The product uses an integrated needle-safety device or improved syringe ergonomics. The opportunity is strongest in hospital and outpatient settings where administration safety has procurement value.

Regional partnership launch

A manufacturer licenses API or finished-product rights to regional distributors. This model is suited to countries where regulatory filing, public tenders, and local manufacturing requirements determine access.

How does Arixtra compare with competing anticoagulants?

Product	Active ingredient	Dosage form	Excipient complexity	Competitive position
Arixtra	Fondaparinux sodium	Prefilled subcutaneous injection	Low	Synthetic pentasaccharide; no HIT cross-reactivity associated with heparin structure
Lovenox and generics	Enoxaparin sodium	Prefilled injection and vial	Low to moderate	Large generic and hospital market
Fragmin	Dalteparin sodium	Injection	Low to moderate	Established low-molecular-weight heparin
Unfractionated heparin	Heparin sodium	Vial and infusion presentations	Low	Low-cost hospital anticoagulant
Direct oral anticoagulants	Various small molecules	Tablets	Solid-dose formulation complexity	Avoid injection and administration burden

Fondaparinux is unlikely to win a broad price competition against mature heparin products. Its commercial value is higher in targeted indications, perioperative protocols, and accounts that value its synthetic composition and dosing profile.

What is the revenue exposure and commercial opportunity?

Arixtra is a mature product with limited branded-growth potential. Revenue exposure is concentrated in a narrower set of hospital and specialty indications than in mass-market anticoagulants.

The commercial opportunity is strongest for companies that can achieve one or more of the following:

• Reliable fondaparinux API supply.
• Lower-cost sterile production.
• Approved prefilled-syringe capacity.
• Hospital tender access.
• Multi-country registration.
• Device differentiation.
• Secondary sourcing for institutional buyers.
• Contract manufacturing for generic applicants.

The excipient component itself is unlikely to create high-margin exclusivity. Sodium chloride and water for injection are commodity materials. Value is more likely to arise from the integrated product: active ingredient, sterile process, container closure, device, regulatory dossier, and supply network.

Key Takeaways

• Arixtra uses a simple preservative-free aqueous formulation based on sodium chloride, water for injection, and pH adjustment.
• Fondaparinux is a synthetic pentasaccharide and follows the generic ANDA pathway, not the biosimilar pathway.
• Core Arixtra composition and exclusivity barriers are mature and have generally expired.
• The principal technical barrier is fondaparinux API synthesis and impurity control.
• The strongest excipient strategy is reference-like formulation with improved syringe, stability, and container-closure performance.
• Commercial differentiation depends more on supply reliability, device design, hospital contracting, and geographic registration than on novel excipients.
• Generic launch risk is primarily operational and manufacturing-based rather than driven by a broad surviving composition patent.
• Licensing opportunities center on API, sterile fill, prefilled syringes, regulatory dossiers, and regional commercialization.

FAQs

Can fondaparinux be formulated without sodium chloride?

Yes, but removing sodium chloride would alter osmolality and require formulation and comparability work. The reference product uses sodium chloride to support an injectable isotonicity profile.

Is Arixtra a biologic drug?

No. Arixtra contains fondaparinux sodium, a chemically synthesized pentasaccharide. Generic versions are reviewed through the ANDA pathway.

Does Arixtra require a preservative?

No. The marketed presentation is a single-dose, preservative-free sterile injection.

Can fondaparinux be sold in a vial instead of a prefilled syringe?

A vial presentation may be technically possible, but it would change the container-closure and administration profile. The applicant would need to address dose accuracy, withdrawal losses, sterility, labeling, and human-factors considerations.

What is the most valuable patent opportunity around fondaparinux?

The most commercially relevant opportunities are likely to involve improved manufacturing processes, impurity reduction, analytical control, container systems, and injection devices rather than a new basic fondaparinux composition patent.

References

1. U.S. Food and Drug Administration. (2023). Arixtra (fondaparinux sodium) injection prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. European Medicines Agency. (2002). Arixtra: European public assessment report. EMA.

4. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. ICH.

5. International Council for Harmonisation. (1995). Q3C: Impurities: Guideline for residual solvents. ICH.